Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionMAb targeting reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B)
Molecular Target Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSpinal cord injury (SCI)
Indication DetailsTreat acute spinal cord injury (SCI)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today